Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation
Open Access
- 1 February 2012
- journal article
- research article
- Published by Informa UK Limited in International Journal of Nanomedicine
- Vol. 7, 731-737
- https://doi.org/10.2147/ijn.s28783
Abstract
Background: Development of anticancer drugs is challenging. Indeed, much research effort has been spent in the development of new drugs to improve clinical outcomes with minimal toxicity. We have previously reported that a formulation of lipid gold porphyrin nanoparticles reduced systemic drug toxicity when compared with free gold porphyrin. In this study, we investigated the delivery and treatment efficiency of PEG surface-modified lipid nanoparticles as a carrier platform. Methods: We encapsulated antitumor drugs into PEG-modified lipid nanoparticles and these were characterized by size, zeta potential, and encapsulation efficiency. The delivery efficiency into tumor tissue was evaluated using a biodistribution study. To evaluate antitumor efficacy, gold porphyrin or camptothecin (a DNA topoisomerase I inhibitor) were encapsulated and compared using an in vivo neuroblastoma (N2A) model. Results: We showed that drug encapsulation into PEG-modified lipid nanoparticles enhanced the preferential uptake in tumor tissue. Furthermore, higher tumor killing efficiency was observed in response to treatment with PEG-modified lipid nanoparticles encapsulating gold porphyrin or camptothecin when compared with free gold porphyrin or free camptothecin. The in vivo antitumor effect was further confirmed by study of tumor inhibition and positive apoptosis activity. Surface modification of lipophilic nanoparticles with PEG increased the efficiency of drug delivery into tumor tissue and subsequently more effective antitumor activity. Conclusion: This specific design of a chemotherapeutic agent using nanotechnology is important in the development of a safe and effective drug in cancer therapy.Keywords
This publication has 29 references indexed in Scilit:
- Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphileInternational Journal of Pharmaceutics, 2012
- Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor StudyJNCI Journal of the National Cancer Institute, 2009
- Inhibition of Akt sensitises neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibitionBritish Journal of Cancer, 2009
- Tumor resistance to apoptosisInternational Journal of Cancer, 2008
- Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted ImmunotherapyClinical Cancer Research, 2008
- Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin levelEuropean Journal Of Cancer, 2006
- Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administrationCancer Letters, 2001
- The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdvances in Enzyme Regulation, 2001
- The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease.2001
- Physico‐chemical requirements for cellular uptake of pAntp peptideEuropean Journal of Biochemistry, 2001